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ABSTRACT
The Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded chemokine 
receptor vGPCR acts as an oncogene in Kaposi’s sarcomagenesis. Until now, the 
molecular mechanisms by which the vGPCR contributes to tumor development remain 
incompletely understood. Here, we show that the KSHV-vGPCR contributes to tumor 
progression through microRNA (miR)-34a-mediated induction of genomic instability. 
Large-scale analyses on the DNA, gene and protein level of cell lines derived from 
a mouse model of vGPCR-driven tumorigenesis revealed that a vGPCR–induced 
upregulation of miR-34a resulted in a broad suppression of genome maintenance 
genes. A knockdown of either the vGPCR or miR-34a largely restored the expression 
of these genes and confirmed miR-34a as a downstream effector of the KSHV-vGPCR 
that compromises genome maintenance mechanisms. This novel, protumorigenic role 
of miR-34a questions the use of miR-34a mimetics in cancer therapy as they could 
impair genome stability.
INTRODUCTION
Kaposi´s sarcoma-associated herpesvirus (KSHV), 
also known as human herpesvirus 8 (HHV-8), is the 
etiological agent of three associated diseases: Kaposi’s 
sarcoma (KS), primary effusion lymphoma (PEL), and 
a plasmablastic form of multicentric Castleman disease 
(MCD). KSHV is a DNA tumor virus that encodes several 
homologues of cellular genes including the G protein-
coupled receptor vGPCR. The receptor shows highest 
homology to the human chemokine receptors CXCR1 and 
CXCR2 and is constitutively active in the ligand-unbound 
state [1]. vGPCR binds a number of human and murine 
CC and CXC chemokines that modulate its constitutive 
activity and, when expressed as a transgene in mice, 
induces KS-like lesions [2].
The presence of viral DNA and proteins can elicit 
a DNA damage response (DDR) and activate DNA 
repair pathways in the infected host cell. However, many 
DNA viruses, including KSHV, are able to subvert the 
growth-suppressive DDR and downregulate DNA repair 
mechanisms [3–5]. Infected cells are thus at high risk 
for an accumulation of genomic aberrations as genome 
integrity relies on the effectiveness of the DDR and DNA 
repair mechanisms. Genomic instability has indeed been 
described in KSHV-infected and primary KS and PEL 
cancer cells [6, 7], but little is known about the molecular 
mechanisms by which KSHV induces genomic instability.
MicroRNAs are short, single-stranded RNAs 
that regulate gene expression on the transcript level [8]. 
Members of the highly conserved microRNA-34 family 
have been implicated as tumor suppressors [9, 10] acting 
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downstream of p53, a major effector in the DNA damage 
response [11]. They are, for example, involved in the 
control of cellular proliferation, cell cycle, apoptosis and 
senescence [9, 12]. These findings led to the development 
of miR-34a mimetics for cancer therapy [13, 14], which 
currently are in phase I clinical trials [13, 14]. More 
recent studies, however, suggested that the miR-34 family 
is dispensable for p53-mediated processes [15] and that 
high miR-34a levels can be beneficial for certain cancer 
cells [16–20]. In this connection, Forte and colleagues 
[21] showed that miR-34a is highly expressed in KSHV-
infected lymphoma cell lines, suggesting a potential role 
of miR-34a in KSHV-dependent tumorigenesis.
Here, we demonstrate that the KSHV-vGPCR 
impairs the expression of a large number of genes required 
for the maintenance of genome integrity. A comparison of 
vGPCR-expressing tumor cell lines that differ significantly 
in their aggressiveness revealed that this repression is 
largely mediated by vGPCR-dependent induction of 
miR-34a, which in turn downregulates these genome 
maintenance genes. Taken together, our data suggest a 
novel, oncogenic role for microRNA-34a as it promotes 
genomic instability and tumorigenesis downstream of the 
KSHV-vGPCR.
RESULTS
vGPCR-expressing tumor cell lines differ in their 
tumorigenicity
We previously described a vGPCR-driven murine 
tumor model (Figure 1A and ref. [22]) that allows 
for the identification of crucial mechanisms of cancer 
development. In this model, BALB/c-3T3 cells were 
retrovirally transduced with the vGPCR oncogene, 
thus generating a cell line that is tumorigenic in 
athymic, immunorestricted BALB/c nu/nu mice due 
to the transforming potential of the vGPCR. These 
“vGPCR-3T3” cells are, however, not tumorigenic in 
immunocompetent BALB/c mice though fragments from 
tumors of BALB/c nu/nu mice grow progressively when 
grafted onto BALB/c mice. Strikingly, cell lines generated 
from tumors of BALB/c mice, named “vGPCR-TC", 
are highly tumorigenic in these mice, in contrast to the 
parental vGPCR-3T3 cell line. Tumor growth of vGPCR-
TC cell lines is still dependent on the vGPCR oncogene 
as shown by shRNA-mediated knockdown of the receptor 
[22]. A detailed analysis of two independently generated 
vGPCR-TC cell lines, termed “vGPCR-TC#1” and 
“vGPCR-TC#2”, revealed a significant difference in their 
tumorigenicity: 7 out of 8 animals injected with vGPCR-
TC#1 cells developed tumors with a median onset (tumor 
volume > 0.02 cm3) of 28 days, whereas only 5 out of 
8 animals receiving the replicate cell line vGPCR-TC#2 
developed tumors with a median onset of 55 days (Figure 
1B). Thus, we were interested in identifying the molecular 
differences between the two tumor cell lines that enable 
the more aggressive growth of vGPCR-TC#1 cells.
To this end, we performed a comprehensive, large-
scale characterization of the two vGPCR-expressing tumor 
cell lines, their parental vGPCR-3T3 cell line and a GFP-
transduced BALB/c-3T3 ("GFP-3T3") control cell line. 
First, we compared the transcriptomes of all cell lines 
using Affymetrix GeneChip 430 2.0 expression arrays 
(Figure 1C). Our data showed that the introduction of the 
vGPCR into BALB/c-3T3 cells had a rather small effect 
on the overall gene expression pattern as only 323 genes 
were differentially expressed (≥ 2-fold, p ≤ 0.05) between 
GFP-3T3 and vGPCR-3T3 cells. In contrast, passaging 
of vGPCR-3T3 cells through nude and BALB/c mice had 
a dramatic effect on global gene expression: 3801 genes 
were regulated between vGPCR-3T3 and vGPCR-TC#1 
cells and, likewise, 3089 genes between vGPCR-3T3 and 
vGPCR-TC#2 cells (Figure 1C). A hierarchical cluster 
analysis of all differentially expressed genes between 
GFP-3T3, vGPCR-3T3, vGPCR-TC#1 and vGPCR-
TC#2 cells revealed that both tumor cell lines share many 
similarities but clearly differ from their parental vGPCR-
3T3 cell line as well as GFP-3T3 control cells (Figure 1C). 
We could confirm these results by mass spectrometry-
based stable isotope dimethyl labeling (DML) which 
allowed us to directly compare changes in protein 
abundance between vGPCR-TC#1 and vGPCR-TC#2 cells 
and their parental vGPCR-3T3 cell line (Figure 1D and 
Supplementary Table 1). DML showed that 2066 out of 
2206 quantified proteins (~94 %) are similarly expressed 
in vGPCR-TC#1 and vGPCR-TC#2 cells (fold-change ≤ 
2). Interestingly, we observed a particular high abundance 
of several chromosome 4- and 9-encoded proteins in 
vGPCR-TC#1 cells (Figure 1D).
The aggressively growing cell line vGPCR-TC#1 
harbors massive genomic amplifications
Based on the strong overrepresentation of 
chromosome 4- and chromosome 9-encoded genes 
and proteins in vGPCR-TC#1 cells we tested for 
copy number variations by array-based comparative 
genomic hybridization (aCGH). aCGH identified major 
amplifications of the chromosome bands 4qC5, 4qC6 
and 9qA1 specifically in vGPCR-TC#1 cells (Figure 2A 
and B). The amplicons on chromosome 4qC5 and C6 are 
made up of several short, closely spaced segments ranging 
from ~5 to ~50 copies. The 9qA1 amplicon, in contrast, 
consists of two adjacent segments with ~18 and ~22 copies 
(Figure 2B). These amplicons encode the oncogenes 
c-Jun (chr4qC5), Yap1 (chr9qA1), Birc2 and Birc3 (both 
chr9qA1) as well as Dcun1d5 (chr9qA1) and the leptin 
receptor (chr4C6). These findings suggest that the vGPCR-
TC#1 cell line, but neither the vGPCR-TC#2 nor the 
parental vGPCR-3T3 cell line, is genomically unstable.
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Figure 1: Large-scale analysis of the transcriptome and proteome of cell lines from the vGPCR mouse tumor model. 
A. The vGPCR-driven mouse tumor model: vGPCR-transduced BALB/c 3T3 cells (“vGPCR-3T3”) induce tumors in athymic BALB/c 
nude mice only; however, tumor fragments from nude mice tumors grew progressively in immunocompetent BALB/c mice and gave rise 
to vGPCR-expressing tumor cell lines (vGPCR-TC#1 and #2) that are capable of directly inducing tumors in BALB/c mice. B. Tumor 
induction and growth rate of vGPCR-TC#1 cells (red) and vGPCR-TC#2 cells (black) in BALB/c mice; each mouse received 1*106 cells 
s.c., n = 8 per group. C. Genome-wide mRNA expression analysis of cell lines derived from the vGPCR-driven tumor model. The Venn 
diagram indicates the overlap of differentially expressed genes from the following comparisons: vGPCR-TC#1 vs. vGPCR-3T3 (orange), 
vGPCR-TC#2 vs. vGPCR-3T3 (blue) and vGPCR-3T3 vs. GFP-3T3 (red). The heat map shows a cluster analysis for all genes that are 
significantly regulated between any two of the following cell lines: GFP-3T3, vGPCR-3T3, vGPCR-TC#1 & #2 (fold-change ≥ 2, p ≤ 
0.05). Spearman’s rank correlation coefficients of indicated cell lines are depicted below the heat map. D. Comparison of relative protein 
abundances by stable isotope dimethyl labeling (DML): the scatter plot depicts changes in protein abundance between vGPCR-TC#1 and 
vGPCR-TC#2 cells; DML ratios (log2) are plotted against combined peptide intensities (log10 H+L); chr9A1 and chr4C5/C6-encoded 
proteins are marked by blue arrows.
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vGPCR-TC#1 and vGPCR-TC#2 cells differ 
markedly for vGPCR-controlled genes
We have previously shown that the tumorigenicity 
of vGPCR-TC cell lines depends on the expression of the 
vGPCR oncogene as a stable knockdown of the receptor 
slowed down tumor growth in nude mice significantly [22]. 
Hence, we were interested in identifying genes that are 
controlled by the vGPCR and their possible contribution 
to the genomic instability and aggressive growth behavior 
of vGPCR-TC#1 cells. To this end, we knocked down 
vGPCR expression in vGPCR-TC#1 cells by lentiviral 
transduction with a set of three specific shRNAs. The 
knockdown efficiency in the newly generated shvGPCR-
TC#1 cell line reached about 85 % on the protein level 
(Figure 3A). A comparison of the gene expression profiles 
of shvGPCR-TC#1 and vGPCR-TC#1 cells identified 1998 
genes (2563 probe sets) to be controlled by the oncogenic 
receptor in vGPCR-TC#1 cells (Figure 3B, purple circles). 
The majority of these probe sets (1654 out of 2563, sum 
of intersections of upper and lower Venn diagram, Figure 
3B) were also differentially expressed between the tumor 
cell lines vGPCR-TC#1 and vGPCR-TC#2 (Figure 3B). 
vGPCR-suppressed genes (upregulated in shvGPCR-TC#1 
when compared to vGPCR-TC#1 cells) were enriched 
among genes that were downregulated in vGPCR-TC#1 
cells relative to vGPCR-TC#2 cells while vGPCR-
activated genes were predominantly higher expressed 
in vGPCR-TC#1 than TC#2 cells (upper Venn diagram, 
Figure 3B). The differential impact of the vGPCR on gene 
expression in vGPCR-TC#1 and vGPCR-TC#2 cells can 
be easily visualized by color coding vGPCR-controlled 
genes in a scatter plot that compares passaging-induced 
changes in gene expression in both tumor cell lines (Figure 
3C). Evidently, almost all vGPCR-activated genes are 
higher expressed in the cell line vGPCR-TC#1 than #2 
(green dots in Figure 3C) while vGPCR-suppressed genes 
are generally lower expressed in vGPCR-TC#1 than in 
vGPCR-TC#2 cells (red dots, Figure 3C).
Further insight into the remarkably different 
regulation of vGPCR-controlled genes in vGPCR-TC#1 
and -TC#2 cells was obtained by color-coding of vGPCR-
controlled genes in scatter plots that display passaging-
induced (x-axis) versus vGPCR-transformation-induced 
(y-axis) changes in gene expression (Figure 3D). The 
vGPCR is, for example, largely responsible for the negative 
correlation between transformation- and passaging 
induced changes in vGPCR-TC#1 cells (Spearman’s rank 
Figure 2: Array-based CGH analysis A. Clustered heat map of segments on chromosome 4 and chromosome 9 for the cell lines GFP-
3T3, vGPCR-3T3, vGPCR-TC#1 and vGPCR-TC#2 (individual arrays are shown). White areas correspond to regions showing no copy 
number alteration. B. DNA copy number profiles: segments with significant changes in their copy number in GFP-3T3, vGPCR-3T3, vGPCR-
TC#1 and vGPCR-TC#2 cells are shown in red (amplifications) or blue (deletions); the diploid status (n = 2) is marked by a black line.
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Figure 3: Identification of vGPCR-controlled genes in vGPCR-TC#1 cells by knockdown of the vGPCR. A. Western 
blot analysis of the efficiency of vGPCR knockdown in vGPCR-TC#1 cells with either a single or three vGPCR-specific shRNAs: the 
simultaneous use of three shRNAs led to a knockdown efficiency (KD) of 85%. B. Venn diagrams showing the overlap between differentially 
expressed genes (fold-change ≥ 2, p ≤ 0.05) between vGPCR-TC#1 and vGPCR-TC#2 cells (blue circle) and vGPCR-controlled genes as 
identified by shRNA knockdown of the vGPCR (shvGPCR-TC#1 vs. vGPCR-TC#1, purple circle). The Venn diagrams break down this data 
to up- and downregulated genes for each comparison. The upper Venn diagram visualizes the overlap for genes that are counter-regulated, 
i.e. downregulated in vGPCR-TC#1 vs. vGPCR-TC#2 cells but upregulated upon knockdown of the vGPCR (vGPCR-suppressed genes) 
and vice versa for vGPCR-activated genes. The lower Venn diagram depicts the overlap for coregulated genes, e.g. downregulated in 
vGPCR-TC#1 cells and also downregulated in shvGPCR-TC#1 (vGPCR-activated) and vice versa for vGPCR-suppressed genes. 
(Continued )
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correlation coefficient ρ for vGPCR-controlled genes 
= -0.55; Figure 3D, left plot). This implies that changes 
in gene expression upon introduction of the vGPCR in 
BALB/c-3T3 cells were mostly reversed in vGPCR-TC#1 
cells. The knockdown of the vGPCR in shvGPCR-TC#1 
cells, however, adjusted the expression levels of vGPCR-
controlled genes to the ones of vGPCR-TC#2 cells and 
abolished the negative correlation observed in vGPCR-
TC#1 cells (ρ(all) = -0.01, for shvGPCR-TC#1 cells vs. 
ρ(all) = -0.37 for vGPCR-TC#1 cells, Figure 3D left and 
right plot). The strikingly similar expression of vGPCR-
controlled genes in shvGPCR-TC#1 and vGPCR-TC#2 
cells could be confirmed by hierarchical cluster analysis 
(Figure 3E): vGPCR-controlled genes show similar 
expression levels in shvGPCR-TC#1 and vGPCR-TC#2 
cells (ρ = 0.92, Figure 3F) that differ strongly from those 
in vGPCR-TC#1 cells (ρ = 0.67 and ρ = 0.68, respectively, 
Figure 3F). The vGPCR knockdown rendered gene 
expression in shvGPCR-TC#1 cells also more similar 
to their parental cell line vGPCR-3T3 (ρ = 0.76 vs. ρ = 
0.73, Figure 3F). The differential expression of vGPCR-
controlled genes is, however, not caused by a different 
abundance of the vGPCR in the tumor cell lines or the 
parental vGPCR-3T3 cell line (Figure 3G). Our results 
suggest that the marked difference in vGPCR-controlled 
gene expression between vGPCR-TC#1 and vGPCR-
TC#2 cells is due to changes downstream of the vGPCR 
oncogene.
vGPCR-dependent suppression of genome 
maintenance pathways in vGPCR-TC#1 cells 
involves downregulation of putative miRNA-34a 
target genes
The amplification and consequent overexpression 
of growth promoting genes encoded on chromosomes 
9 (9qA1) and 4 (4qC5, 4qC6) most likely contributes to 
the higher tumorigenicity of vGPCR-TC#1 cells (Figure 
1B). This raises the question about the underlying 
mechanisms that promote genomic instability and the 
possible role of the vGPCR in this process. To address 
these questions, we performed a pathway enrichment 
analysis that revealed a strong overrepresentation 
of pathways crucial for the maintenance of genomic 
integrity (Figure 4A) such as DNA replication, Cell cycle, 
Chromosome maintenance, p53 signaling, G2 to M DNA 
damage checkpoint, and Activation of ATR in response 
to replication stress. We further identified DNA repair 
pathways including Homologous recombination, Base 
excision repair, Nucleotide excision repair, Mismatch 
repair and the Fanconi anemia pathway. Genes from these 
pathways were highly enriched among genes that were 
downregulated in vGPCR-TC#1 cells when compared to 
vGPCR-TC#2 cells (Figure 4A, column 4) or the parental 
vGPCR-3T3 cells (Figure 4A, column 2), but not in 
vGPCR-TC#2 cells compared to the parental cell line 
(Figure 4A, column 3). Strikingly, these genes were 
largely suppressed by the vGPCR as the knockdown of 
vGPCR in shvGPCR-TC#1 cells restores their expression 
levels (Figure 4A, column 5).
The overrepresentation of genes of the pathway 
miRNA regulation of DNA damage response hinted at a 
possible involvement of miRNAs in the onset of vGPCR-
induced genomic instability. A gene set enrichment 
analysis for microRNA target genes revealed a strong 
enrichment of microRNA-34 targets among genes 
downregulated in vGPCR-TC#1 cells relative to vGPCR-
TC#2 or vGPCR-3T3 cells (Figure 4B, columns 2 & 4). 
As seen for the genome maintenance pathways, the 
expression of microRNA-34 target genes was also restored 
upon vGPCR knockdown (Figure 4B, column 5). This 
implies that at least one member of the microRNA-34 
family is critically involved in the vGPCR-dependent 
suppression of genome maintenance mechanisms.
To assess the expression of microRNA-34 family 
members in our cell lines we used a stem-loop RT-qPCR 
approach [23, 24] specific for the mature form (5p) of miR-
34a, b or c (Figure 4C). miR-34a was significantly higher 
expressed in both vGPCR-TC#1 and GFP-3T3 cells than 
in vGPCR-3T3 or the vGPCR-TC#2 cells. Interestingly, 
miR-34a expression is abolished in shvGPCR-TC#1 cells, 
indicating that the vGPCR activates miR-34a expression 
in vGPCR-TC#1 cells. In contrast, we did not observe a 
marked difference in miR-34b and miR-34c expression 
between the cell lines analyzed. The expression pattern 
of miR-34a fits the enrichment pattern of microRNA-34 
Figure 3: (Continued ) C. Scatter plot comparing passaging-induced changes in gene expression for vGPCR-TC#1 and vGPCR-
TC#2 cells, in each case relative to the parental cell line vGPCR-3T3. vGPCR-controlled genes upregulated upon vGPCR knockdown in 
shvGPCR-TC#1 cells (compared to vGPCR-TC#1 cells) are shown in red (vGPCR-suppressed) and genes downregulated upon vGPCR 
knockdown in green (vGPCR-activated); included are all probe sets that were significantly regulated in at least one comparison (fold-
change ≥ 2, p ≤ 0.05); chr9A1 or chr4C5/C6-encoded genes are marked blue. The figure includes Spearman’s rank correlation coefficients 
ρ for (i) all, (ii) vGPCR-independent, and (iii) and vGPCR-controlled gene probe sets. D. Scatter plots comparing passaging-induced 
gene expression changes (x-axis) versus vGPCR transformation-induced changes (y-axis) for vGPCR-TC#1 (left), vGPCR-TC#2 (middle) 
or shvGPCR-TC#1 cells (right); red and green dots mark vGPCR-controlled genes as described for panel C. E. Clustered heat maps 
comparing mRNA expression of vGPCR-controlled genes in GFP-3T3, vGPCR-3T3, vGPCR-TC#1, vGPCR-TC#2 and shvGPCR-TC#1 
cells; left: vGPCR-activated genes, right: vGPCR-suppressed genes as identified by vGPCR knockdown in the vGPCR-TC#1 cell line. F. 
Correlation plot with color-coded Spearman’s rank correlation coefficients ρ for vGPCR-controlled genes in indicated cell lines. G. Western 
blot of vGPCR abundances in vGPCR-3T3, vGPCR-TC#1 and vGPCR-TC#2 cells.
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Figure 4: vGPCR- and miR-34a-dependent suppression of genome maintenance pathways. A. Pathway enrichment 
analysis among differentially expressed genes (fold-change ≥ 2, p ≤ 0.05) for the indicated cell line comparisons; pathways enriched 
among upregulated genes show up in red and pathways enriched among downregulated genes show up in in blue according to the z-scores. 
B. Enrichment of miR-34 target genes (as identified by He et al. [9]) among up- or downregulated genes in the indicated comparisons. 
C. Expression of miR-34 family members (5p) as determined by stem-loop RT-qPCR. MicroRNA expression was normalized to the small 
RNA sno202; p-values have been determined by an unpaired t-test (n = 3). D. Identification of potential miR-34a targets among the 678 
genes that are downregulated in vGPCR-TC#1 vs. vGPCR-TC#2 cells and upregulated upon knockdown of the vGPCR in shvGPCR-TC#1 
cells (red circle). The Venn diagrams show the overlap of this gene set with experimentally identified miR-34a target gene sets taken from 
He et al. (orange) [9], Kaller et al. (purple) [26], Ebner and Selbach (blue) [27] and Lal et al. (green) [25].
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target genes as depicted in Figure 4B: microRNA-34 
targets are enriched among the downregulated genes 
if miR-34a-high cell lines (vGPCR-TC#1, GFP-3T3) 
were compared to miR-34a-low cell lines (vGPCR-
3T3, vGPCR-TC#2 and shvGPCR-TC#1). Our results 
strongly suggest that miR-34a is indeed responsible for 
the enrichment pattern shown in Figure 4B.
Next, we assessed the number of potential miR-34a 
target genes within the set of the 678 vGPCR-suppressed 
genes (925 probe sets) that are downregulated in vGPCR-
TC#1 vs. vGPCR-TC#2 cells (Figure 3B, upper Venn 
diagram). To this end, we overlaid our set of 678 vGPCR-
suppressed genes with 4 data sets of experimentally 
identified miR-34a target genes (Figure 4D): He et al. [9] 
as well as Lal et al. [25] identified miR-34a targets on 
gene expression level using microarrays whereas Kaller 
et al. [26] and Ebner and Selbach [27] used a pulsed 
SILAC approach to identify targets at the protein  level.
In a combined overlay 284 out of 678 vGPCR-suppressed 
genes (42 %) were identified as experimentally validated 
miR-34a target genes. Another 125 of these 678 genes 
were bioinformatically predicted miR-34a target genes 
that were identified using TargetScan, RNAhybrid, 
miRanda, miRBase or Pictar.
Tough Decoy RNA-mediated knockdown of 
miR-34a in vGPCR-TC#1 cells results in the 
upregulation of genome maintenance genes
So far, our data suggested that the vGPCR-mediated 
upregulation of miR-34a in vGPCR-TC#1 cells led to the 
suppression of the genome maintenance mechanisms. 
To verify this hypothesis, we knocked down miR-34a 
(5p) in vGPCR-TC#1 cells by a Tough Decoy RNA 
(TuD) approach [28] and analyzed the gene expression 
profile of the resulting TuD-miR-34a-TC#1 cell line. 
The knockdown of miR-34a (~85%, Figure 5A) led to a 
significant change in the expression levels of 2164 genes 
(2810 probe sets; Figure 5B). Strikingly, we observed 
highly similar gene expression profiles for TuD-miR-34a-
TC#1 cells and shvGPCR-TC#1 cells (ρ = 0.94, Figure 
5C). Consequently, the distribution of miR-34a-regulated 
genes (Figure 5D) mimicked the one of vGPCR-regulated 
genes (Figure 3C) in a scatter plot depicting passaging-
induced gene expression changes for vGPCR-TC#1 and 
-TC#2 cells. This confirms that miR-34a plays a major 
role downstream of the vGPCR oncogene. In total, we 
identified 707 genes that were suppressed by both the 
vGPCR- and miR-34a, many of which belong to genome 
maintenance pathways (Supplementary Table 2).
The heat map in Figure 6 visualizes the expression 
levels of selected genes stemming predominantly from 
genome maintenance pathways. In Table 1, these genes 
have been classified according to their Gene Ontology 
(GO) terms showing that many genes are associated to the 
cell cycle, DNA repair, DNA replication or chromosome 
organization. Pathway associations taken from the KEGG 
pathways, WikiPathways, and Pathway Commons 
databases are listed in Supplementary Table 2 while 
Supplementary Table 3 contains the corresponding GO 
terms, fold-changes, bioinformatically predicted miR-34a 
target genes and references for experimentally identified 
miR-34a target genes. The color tags in Figure 6 mark 
miR34-a target genes as experimentally identified in other 
studies (red dots), bioinformatically predicted (blue dots) 
or identified by our Tough Decoy RNA-mediated knock 
down (green dots). The heat map clearly shows that the 
expression levels of the genome maintenance genes were 
much lower in cell lines expressing high levels of miR-34a 
(GFP-3T3 and vGPCR-TC#1) than in cell lines expressing 
low levels of miR-34a (vGPCR-3T3, vGPCR-TC#2, 
shvGPCR-TC#1, TuD-miR34a-TC#1). This result was 
confirmed for 10 randomly selected genes by RT-qPCR 
(see Supplementary Figure 1).
In a second approach we analyzed the effect of 
miR-34a overexpression on global gene expression levels 
in vGPCR-3T3 and vGPCR-TC#2 cells. The lentivirally 
transduced cell lines miR-34a-vGPCR-3T3 and miR-
34a-vGPCR-TC#2 showed a 9-fold and 3.4-fold increase 
in miR-34-a expression, respectively (Supplementary 
Figure 2A). Overexpression of miR-34a led to significant 
changes in the expression level of 2907 genes in vGPCR-
3T3 cells but only 732 genes in vGPCR-TC#2 cells. 
Regarding the genome maintenance genes shown in 
Figure 6, we observed a downregulation of 51 genes in 
miR-34a-vGPCR-3T3 cells and 30 genes in miR-34a-
vGPCR-TC#2 cells relative to the unmodified cell lines 
(see Supplementary Figure 2B).
Strikingly, almost all genome maintenance genes 
were upregulated upon the Tough Decoy knockdown 
while overexpression of miR-34a led to a downregulation 
of a subset of these genes. Taken together, these findings 
strengthen our argument that miR-34a is crucial for 
the repression of these genome maintenance genes 
in the setting of our mouse model for vGPCR-driven 
tumorigenesis and that it contributes to the onset of 
genomic instability.
DISCUSSION
DNA tumor viruses have profound effects on 
host cell processes including those relevant to genome 
maintenance. The recognition of viral DNA by the host 
leads to an activation of DNA damage checkpoints and 
DNA repair mechanisms that protect genomic integrity and 
constitute a natural barrier to tumor progression. As part 
of their survival strategies DNA tumor viruses suppress 
the DNA damage response (DDR) to create an S-phase 
like environment suitable for viral replication [3, 4, 29, 
30]. However, the suppression of genome maintenance 
mechanisms can induce genomic instability as reflected 
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Figure 5: Identification of miR-34a-regulated genes in vGPCR-TC#1 cells by using a Tough Decoy RNA-mediated 
knockdown approach. A. Efficiency of miR-34a knockdown in TuD-miR-34a-TC#1 cells that were generated by lentiviral transduction 
of vGPCR-TC#1 cells with a Tough Decoy RNA against miR-34a-5p. miR-34a-5p expression has been assessed by stem-loop RT-qPCR 
and normalized to sno202. Knockdown efficiency was determined via the ratio of TuD-miR-34a-TC#1 to vGPCR-TC#1 pLKO.1 neo 
(empty vector control). B. Cluster analysis for genes that were significantly regulated by the knockdown of miR-34a. The clustered heat 
map to the left compares the mRNA expression level for all probe sets that were upregulated following miR-34a knockdown in TuD-miR-
34a-TC#1 vs. vGPCR-TC#1 cells, the heat map to the right all genes that were downregulated as a result of the miR-34a knockdown. 
C. Matrix with Spearman’s rank correlation coefficients ρ of miR-34a-regulated genes (gene probe sets) as determined by the miR-34a 
knockdown for the indicated cell lines. D. Scatter plot comparing passaging-induced changes in gene expression for vGPCR-TC#1 and 
vGPCR-TC#2 cells, each relative to the parental cell line vGPCR-3T3. miR-34a-controlled genes that were upregulated upon miR-34a 
knockdown in TuD-miR34a-TC#1 cells (compared to vGPCR-TC#1 cells) are shown in red (miR-34a-suppresed) and those that were 
downregulated upon miR-34a knockdown are shown in green (miR-34a-activated); included are all probe sets that were significantly 
regulated in at least one comparison (fold-change ≥ 2, p ≤ 0.05).
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Figure 6: Genes from genome maintenance pathways are suppressed by both the vGPCR and miR-34a. The clustered heat 
map depicts the signal intensities of vGPCR-suppressed genes from genome maintenance pathways that were significantly downregulated 
in vGPCR-TC#1 vs. vGPCR-TC#2 and upregulated in shvGPCR-TC#1 vs. vGPCR-TC#1 cells. miR-34a target genes are marked by (i) red 
dots for experimentally identified targets (references see column “Pubmed ID” in Supplementary Table 3); (ii) blue dots for bioinformatically 
predicted targets using TargetScan, Pictar, miRanda, miRBase, or RNAHybrid; and (iii) green dots for miR-34a target genes identified via 
Tough Decoy knockdown of miR-34a-5p.
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by the increased mutation rate and accelerated acquisition 
of chromosomal aberrations of the infected cells, which 
may lead to the onset of tumorigenesis [31, 32]. There is 
now increasing evidence that both latent and lytic KSHV 
proteins are able to induce genomic instability, however, 
a role of the KSHV-vGPCR in this process has so far not 
been described.
Until now, neither KSHV-vGPCR nor microRNA-
34a has been implicated in the onset of genomic 
instability. However, using a mouse model of vGPCR-
driven tumorigenesis, we clearly observed a vGPCR-
dependent downregulation of numerous genome 
maintenance pathways and a striking accumulation of 
genetic aberrations in an aggressively growing tumor cell 
line expressing high levels of miR-34a. In stark contrast, 
a second tumor cell line expressing low levels of miR-
34a showed no suppression of genome maintenance 
pathways and lacked massive genomic aberrations. 
By separately knocking down the vGPCR and miR-
34a we could demonstrate that the downregulation of 
genome maintenance genes relied on the vGPCR and its 
downstream effector miR-34a. In addition, overexpression 
of miR-34a in either the parental vGPCR-3T3 or vGPCR-
TC#2 cells led to a downregulation of a number of genome 
maintenance genes (see Supplementary Figure 2B), an 
effect that was stronger in vGPCR-3T3 than in vGPCR-
TC#2 cells. This might reflect the higher expression of 
miR-34a in miR-34a-vGPCR-3T3 compared to miR-34a-
vGPCR-TC#2 cells and most likely cell type-dependent 
effects of miR-34a expression.
Numerous miR-34a target genes identified in this 
study are crucially involved in processes such as DNA 
replication, chromosome maintenance, the DNA damage 
response and several DNA repair pathways including 
Table 1: Genes from genome maintenance pathways grouped by Gene Ontology (GO) terms
Gene Ontology term Genes
Cell cycle Aurka, Ccna2, Ccnb1, Ccnb2, Cnd1, Ccne1, Ccne2, Cdc20, Cdc25b, 
Cdc25c, Cdk1, Cdc45, Cdc6, Cdkn1a/p21, Cdkn3, Cep57, Cks2, Foxm1, 
Gas2l3, Kif20b, Mybl2, Plk1, Plk4, Rbl2, Rrm2, Spag5, Spc25, Tgfb1, 
Trp53, Wee1
Cell cycle arrest Ccnd1, p21/Cdkn1a, Cdkn3, Chek1, Chek2, Gas2l3, Kif20b, Tgfb1, Trp53
CENP-A containing nucleosome assembly Casc5, Cenpa, Cenpi, Cenpn, Cenpp, Cenpq, Cenpu, Cenpw, Hjurp, 
Mis18bp1
Centrosome Aurka, Kif11, Cep55, Cep57, Aspm, Ccnf, Xpo1, Sgol1, Xrcc2
Checkpoints Bub1, Bub1b, Mad2l1, Plk1, Ttk, Wee1, Brip1, Casc5, Cdc20, Cdc6, Chek1, 
Chek2, Clspn, Dbf4, H2afx
Chromosome condensation Cdca5, Ncapd2, Ncapd3, Ncapg, Ncapg2, Ncaph, Smc2, Smc4
Chromosome segregation Aurkb, Birc5, Bub1, Bub1b, Cdca2, Cenpe, Cenpf, Dlgap5, Ercc6l, Esco2, 
Espl1, Incenp, Kif2c, Kntc1, Mis18a, Ndc80, Nuf2, Pttg1, Rangap1, Sgol1, 
Ska1, Ska3, Spag5, Spc25
Mitotic spindle organization Nusap1, Nsl1, Rangap1, Stmn1, Tacc3, Tpx2, Ttk
Cytokinesis/cell division/mitosis Aurkb, Cep55, Cep57, E2f8, Gas2l3, Kif20a, Kif22, Kif23, Nusap1, 
Racgap1, Prc1, Xrcc2
DNA replication Ccne1, Ccne2, Cdc25c, Cdc6, Cdk1, Cdc45, Cdca2, Cdca3, Cdt1, Chaf1b, 
Chek1, Chtf18, Clspn, Dbf4, Dna2, Dscc1, Fen1, Gins1, Gins2, Gmnn, 
Hmga1, Mcm10, Mcm2, Mcm3, Mcm4, Mcm5, Mcm6, Mcm7, Orc1, Orc6, 
Pcna, Pola1, Pold1, Pole, Pole2, Prim1, Rfc3, Rfc4, Rrm1, Rrm2, Tk1, 
Top2a, Rpa1, Rpa2, Xrcc2
DNA damage response Chek1, Chek2, Topbp1, Clspn, Blm, Brca1, Rpa1, Rpa2, H2afx,
DNA repair Blm, Brca1, Cdk1, Chaf1b, Clspn, Dna2, Eme1, Esco2, Exo1, Fanca, Fancb, 
Fancd2, Fen1, Fignl1, Foxm1, Gen1, H2afx, Hmga1, Hmga2, Hmgb2, 
Hmmr, Lig1, Mms22l, Mre11a, Neil3, Palb2, Pcna, Pola1, Pole, Pole2, 
Pttg1, Rad18, Rad51, Rad51ap1, Rad54l, Rfc3, Rfc4, Rpa1, Rpa2, Smc2, 
Smc4, Top2a, Topbp1, Trp53, Ube2t, Ung
DSB repair via homologous recombination Blm, Brca1, Dna2, Eme1, Exo1, Fignl1, Gen1, H2afx, Mms22l, Palb2, 
Rad51, Rad51ap1, Rad54l, Rpa1, Rpa2, Xrcc2
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DNA double-strand break (DSB) repair via homologous 
recombination. In line with our results, Ebner and 
Selbach [27] and Lal and colleagues [25] have recently 
shown an enrichment of certain genome maintenance 
pathways among miR-34a target genes: DNA replication 
and cell cycle in the case of Ebner and Selbach and 
DNA replication, cell cycle, G1 to S control and DNA 
repair in the case of Lal et al. [25]. A study by Kofman 
et al. [33] demonstrated that miR-34a can induce DNA 
damage by greatly increasing the number of cells that 
undergo mitotic catastrophe; as this induced apoptosis, 
the authors concluded that miR-34a contributes to genome 
surveillance. A survival of only a few of these genomically 
unstable cells could, however, mark the onset of cancer.
Another crucial aspect for the maintenance of 
genomic integrity is accurate DNA replication [34]. We 
found that miR-34a targets many factors involved in the 
initiation of DNA replication, such as most components 
of the CMG (Cdc45, MCM, GINS) helicase, e.g. Cdc45, 
Mcm2-7, Gins1, Gins2 as well as Cdt1, Cdc6, and 
Mcm10. Downregulating these factors diminishes the 
cellular capacity to deal with replication stress, as marked 
by stalled or collapsed replication forks [34, 35], by 
reducing the overall number of licensed origins. An excess 
of licensed, but dormant, origins that are only activated 
upon replication stress is necessary to ensure complete 
replication of the genome [36]. In this sense, an excess 
of Mcm proteins prevents genomic instability [37, 38], 
whereas insufficient levels of Mcm can cause genomic 
instability [39, 40] and cancer [41]. Furthermore, many 
DNA repair pathways including base excision repair 
(BER), nucleotide excision repair (NER) and mismatch 
repair (MMR) as well as the DSB repair via HR are 
suppressed in a vGPCR- and miR-34a-dependent manner. 
The tumor suppressor BRCA1, for example, is critically 
involved in DSB repair, favoring the failsafe HR over 
the more error-prone NHEJ pathway [42]. BRCA1 also 
possesses an HR-independent function in the repair of 
DNA interstrand crosslinks (ICL) as it unloads the CMG 
complex from stalled replication forks [43]. It has recently 
been described as a miR-34a target [9, 25], which we 
verified by the Tough Decoy knockdown of miR-34a (see 
Figure 6).
Other target genes of miR-34a comprise Clspn, 
Topbp1 or Blm. Claspin (Clspn) is a mediator in the DNA 
damage response and important stabilizer of replication 
forks [44] and its depletion increases the formation of 
chromosomal aberrations. Topbp1, another mediator 
in the DDR, interacts with the RecQ helicase BLM to 
maintain genomic stability [45]. BLM suppresses the 
recombination of sister strands during the resolution of 
the double Holliday junction in HR thereby preventing 
copy number changes [46]. Disruption of the BLM gene 
causes Bloom´s syndrome, a disease that is marked by a 
strong predisposition to genomic instability and cancer 
[47]. Both the vGPCR and miR-34a suppress also a large 
number of genes involved in chromosome condensation 
(e.g. Smc2, Smc4, Ncapd2, Ncapd3, Ncapg), chromosome 
segregation (e.g. Bub1, Esco2, Espl1), organization of the 
centrosome (e.g. Cep55, Cep57) and the establishment of 
the mitotic spindle (e.g. Nusap1, Nsl1). They also suppress 
most members of the chromosomal passenger complex, 
including Aurora kinase B, Incenp and survivin, being the 
central regulator of mitosis. We also found a large number 
of cell cycle genes to be downregulated in the miR-34a-
high tumor cell line including the well-known miR-34a 
target gene Ccne2 [9, 25, 27] and many genes involved 
in the induction of cell cycle arrest such as p21/Cdkn1a 
or Gas2l3 whose depletion has been shown to induce 
genomic instability [48].
Until now, miR-34a has been mostly assigned a 
proapoptotic, tumor-suppressive function [9, 12, 49]. 
However, the effect of endogenous or artificial miR-34a 
expression seems to be highly cell type- and context-
dependent: For example, a knockdown of miR-34a in 
HeLa cells that express this microRNA endogenously 
reduces their proliferation rate [19]. Similarly, miR-34a 
inhibits apoptosis and thus promotes the expansion of 
myeloid-derived suppressor cells [50]. Studies by Bhatt 
et al. [16] and Kato et al. [17] showed that miR-34a can 
act cytoprotectively by increasing the survival of cisplatin-
treated and irradiated cells. In line with a potentially 
protumorigenic role, upregulation of miR-34a has been 
reported in many cancers [18-20, 51]. Although p53 is a 
well-known inducer of the microRNA-34 family [9, 12], 
Concepcion and colleagues [15] convincingly showed 
that microRNA-34 is not functionally required for p53-
dependent processes in replicative senescence, oncogene-
activation or the response to DNA damage. Moreover, 
miR-34a/b/c triple knockout mice showed no increased 
tumor formation rate, very much unlike p53 knockout 
mice, and miR-34-deficient thymocytes were equally 
resistant to radiation-induced apoptosis as their wild type 
counterparts.
The expression of miR-34a can also be induced 
independently of p53, e.g. by TAp73, retinoic acid 
phorbol ester or oncogenic stress [14] and NF-κB-binding 
to the miR-34a promoter has been shown to increase 
transcriptional activity [20]. Interestingly, Forte and 
colleagues [21] showed that miR-34a is highly expressed in 
KSHV-infected cell lines. Our data indicate that the vGPCR 
is critical for the upregulation of miR-34a in KSHV-
infected cells, potentially also in an NF-κB-dependent 
manner since NF-κB is an important downstream 
signaling pathway of the vGPCR [52]. vGPCR-
dependent upregulation of miR-34a could therefore aid 
virus replication and persistence by downregulating the 
DNA damage response and DNA repair. This hypothesis 
is supported by a study by Moody et al. [53] where the 
authors identified cellular target genes for the 12 KSHV-
encoded microRNAs K1-K12. These include a number of 
genome maintenance genes such as MCM subunits, Plk1, 
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Wee1, Bub1 or cyclins that are also downregulated by the 
vGPCR and miR-34a in our tumor model.
The similar abundance of the vGPCR in miR-34a-
high and miR-34a-low tumor cell lines suggests that these 
cell lines differ in terms of vGPCR activity. As it is known 
that chemokines modulate the signaling activity of the 
vGPCR and that the modulation of vGPCR´s signaling 
activity is crucial for its tumorigenic potential [54], we 
speculate that the differential vGPCR activity might result 
from an altered expression of vGPCR ligands. The vGPCR 
can bind several human and murine CXC chemokines that 
modulate its activity by either acting as agonists (e.g. 
CXCL1, CXCL3), antagonists (e.g. CXCL10, CXCL12) 
or neutral antagonists (e.g. CXCL5). The latter have 
no direct effect on receptor activity but compete with 
antagonists for receptor binding [55]. The generally low 
vGPCR activity in the BALB/c-3T3 background, as 
reflected by the moderate change in gene expression upon 
introduction of the vGPCR in BALB/c-3T3 cells could 
be a consequence of very high Cxcl12 expression in all 
cell lines investigated in this study (Supplementary Figure 
3). However, in the aggressively growing tumor cell line, 
receptor activity could be protected by the upregulation of 
the neutral ligand Cxcl5 (32-fold relative to vGPCR-3T3) 
that competes with the antagonist CXCL12 for receptor 
binding. CXCL5 binding may enable a higher vGPCR 
activity and promote miR-34a expression whereas low 
vGPCR activity seems to suppress miR-34a expression as 
observed in the vGPCR-transformed BALB/c-3T3 cells or 
the less aggressive, miR-34a-low tumor cell line.
The genomic instability of the miR-34a-high tumor 
cell line was reflected in high-copy amplicons coding 
for the oncogenes Yap1, Birc2, Birc3, Dcun1d5 (all on 
9A1) or the leptin receptor (4C6). The chromosome 9A1 
amplicon has been described before in mouse tumor 
models [56, 57] and corresponds to the human 11q22 
amplicon that is frequently found in cancers, especially 
in squamous cell carcinomas of mucosal origin where it is 
associated with an aggressive phenotype and poor clinical 
outcome [58]. The 9A1 amplicon might be favorable for 
vGPCR-mediated tumorigenesis as it harbors oncogenes 
that are regulated by the vGPCR. Only recently, vGPCR-
dependent Yap1 activation via suppression of the Hippo 
pathway has been shown [59]. Likewise, the Birc3 
gene is known to be vGPCR-controlled [60]. Hence, 
we observed a significant reduction in the expression of 
several chromosome 9A1-encoded genes upon vGPCR 
knockdown (Supplementary Figure 4), which points to 
a supportive role of this amplicon in vGPCR-dependent 
transformation and a possible function of these genes in 
Kaposi’s sarcomagenesis. The leptin receptor, an important 
gene in the 4C6 locus, may be similarly important as 
it is known to induce proliferation and secretion of 
proangiogenic and immunosuppressive VEGFA [61]. We 
could also show that leptin activates potent oncogenic 
pathways depending on JAK2/STAT3, AKT and ERK1/2 
in the tumor cell line that carried a high-copy amplicon on 
the locus of the leptin receptor (Supplementary Figure 5).
Summing up, our data provide compelling evidence 
that high miR-34a levels as induced by the KSHV-encoded 
oncogenic chemokine receptor vGPCR can promote 
genomic instability, an enabling hallmark of cancer and 
powerful toolkit for developing cancer cells, which boosts 
the mutation rate. In view of recent publications that also 
support a protumorigenic role of miR-34a, the concept of 
using miR-34a mimetics in cancer therapy [13, 14] should 
be viewed with caution as such a replacement therapy 
might promote genomic instability.
MATERIALS AND METHODS
Cell lines and cell culture
The generation of the BALB/c-3T3-derived cell 
lines vGPCR-3T3 and GFP-3T3 has been described 
previously [22]. The tumor-derived cell lines vGPCR-
TC#1 and -#2 were established from tumors grown in 
BALB/c mice as described by Thirunarayanan et al. [22]. 
In brief, vGPCR-3T3 cells (5x105 cells/mouse) gave rise to 
tumors in BALB/c nude mice. Fragments of these tumors 
were transplanted s.c into the flank of immunocompetent 
BALB/c mice. Tumors from BALB/c mice were then 
minced and tumor-derived cells cultured for two to 
three weeks under puromycin selection, resulting in a 
puromycin-resistant population of vGPCR expressing 3T3 
tumor cells. shvGPCR-TC#1 and TuD-miR-34a-TC#1 
cells were generated by lentiviral transduction of vGPCR-
TC#1 cells with either vGPCR-specific shRNAs or a miR-
34a-5p-specific Tough Decoy RNA (see below).
All cell lines were grown in low glucose DMEM 
supplemented with 10 % heat-inactivated newborn calf 
serum, penicillin/streptomycin, non-essential amino 
acids and L-glutamine; shvGPCR-TC#1 and TuD-miR-
34a-TC#1 cells were maintained under 100 - 250 µg/ml 
G418 in the standard medium; HEK293T for lentivirus 
production were kept in high glucose DMEM, 10 % 
heat-inactivated fetal calf serum, penicillin/streptomycin, 
L-glutamine and sodium pyruvate.
Lentiviral particle generation and transduction
Generation of shvGPCR-TC#1 cell line
vGPCR-specific shRNAs have been cloned in-
between AgeI and EcoRI restriction sites of pLKO.1 neo (a 
kind gift of Sheila Stewart). HEK293T cells have been co-
transfected with shvGPCR-pLKO.1 neo, pLP1, pLP2 and 
pCMV-VSV-G (Invitrogen) using linear PEI (MW 40.000, 
Polysciences). Virus-containing supernatants were sterile-
filtrated (0.45 µm) and concentrated by ultracentrifugation 
(3 hrs, 50.000 g, 4 °C) or used freshly for transduction 
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of vGPCR-TC#1 cells. Transduced cells were selected in 
medium containing 500 – 1000 µg/ml G418 (Genaxxon) 
and maintained in medium containing 100 – 250 µg/ml 
G418.













Generation of TuD-miR-34a-TC#1 cell line
A Tough Decoy RNA (according to Haraguchi et 
al. [28] directed against the 5p product of mmu-miR-
34a (miRBase accession number: MIMAT0000542) was 
cloned in-between the AgeI and EcoRI restriction sites 
of pLKO.1 neo (a kind gift of Sheila Stewart). Lentiviral 
particle generation and transduction was performed as 
described above. The Tough Decoy RNA insert (TuD-miR-
34a-5p) was synthesized by GeneArt, Lifetechnologies.






Generation of miR-34a-overexpressing cell lines
vGPCR-3T3 and vGPCR-TC#2 cells were 
lentivirally transduced with MmiR3342-MR12 
(GeneCopoeia) coding for mouse pre-miR34a. Transduced 
miR-34a-vGPCR-3T3 and miR-34a-vGPCR-TC#2 cells 
were selected using G418.
Gene expression profiling and bioinformatic 
analyses
Total RNA was isolated using ZymoResearch´s 
Quick-RNATM MiniPrep kit. RNA quality was assessed 
with Agilent´s Bioanalyzer 2100 using the RNA 6000 
Nano kit. RNA was reverse-transcribed, labeled and 
fragmented using the Affymetrix 3´IVT Express Kit and 
hybridized to Affymetrix GeneChip 430 2.0 arrays. Cell 
lines have been analyzed in duplicates or triplicates. 
Affymetrix CEL files were analyzed using the open-source 
software AltAnalyze (Gladstone Institutes, University 
of California, San Francisco) using a moderated t-test. 
Differentially expressed genes were identified by a fold-
change of at least 2 and a p-value (Benjamini-Hochberg 
adjusted) of ≤ 0.05. Scatter plots were generated in 
Microsoft Excel by plotting fold-changes (log2) in 
gene expression whereby probes had to be significantly 
regulated in at least one of the two comparisons shown in 
the plot. Spearman’s rank correlation coefficients ρ were 
calculated using the following formula: r = 1 - ((6 *∑d2)/ 
(n2 * (n-1)); n = number of elements in comparison, 
d = difference of ranks. Enriched pathways (from the 
KEGG, WikiPathway and PathwayCommon databases) 
as well as z-scores for microRNA-34 target genes and 
bioinformatically predicted miR-34a targets have been 
identified via GO Elite integrated into Altanalyze (data 
set for miRNA-34 targets was taken from He et al. [9] 
via the database Amadeus Metazoan compendium). Venn 
diagrams and clustered heat maps of gene expression data 
(log2 signal intensities) have been generated in AltAnalyze. 
Clustering was based on cosine similarity measures with 
(red-blue color scheme) or without (yellow-black color 
scheme) normalization on row median values. Raw 
data files were deposited in the ArrayExpress database 
(accession number E-MTAB-3393).
References (Pubmed IDs) for miR-34a target genes 
can be found in Supplementary Table 3.
Relative protein quantification via stable isotope 
dimethyl labeling
Changes in relative protein abundance for the cell 
lines vGPCR-3T3, vGPCR-TC#1 and vGPCR-TC#2 
were determined by dimethyl labeling. All pairwise 
comparisons were performed in triplicates. Protein 
extracts were prepared in denaturation buffer (6 M urea, 
2 M thiourea, 10 mM HEPES-KOH pH8.0), sonicated 
to shear DNA and subsequently ultra-centrifuged at 
100.000 g. Protein concentrations were determined by 
Bradford assay and 20 µg of each sample were taken for 
in-solution digestion. For tryptic in-solution digestion, 
samples were reduced with 1 mM tris(2-carboxyethyl) 
phosphine (TCEP) and free sulfhydryl groups 
carbamidomethylated using 5.5 mM choloroacetamide. 
Proteins were pre-digested with 0.5 µg sequencing grade 
endopeptidase LysC (Wako) for 3 hrs at room temperature 
and subsequently diluted with four volumes of 50 mM 
ammonium-bicarbonate. Tryptic digest was performed 
with 1 µg sequencing grade trypsin (Promega) for 8 h and 
stopped by acidification using 10% trifluoroacetic acid. 
The entire digest protocol was performed as described in 
Kanashova et al. [62]. Peptides were purified using C18 
stage-tips (3M) [63]. The eluted peptides were lyophilized 
in a speed-vac and reconstituted with 100 µl 100 mM 
triethylammonium bicarbonate (TEAB) and dimethyl-
labeled in solution [64] using light (+28 Da) or heavy 
formaldehyde (+32 Da) at a final concentration of 0.15 
% in the presence of 0.8 % sodium cyanoborohydride. 
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The reaction was carried out over night, quenched with 
16 µl ABC buffer and acidified by adding 8 µl 50 % 
TFA. Dimethyl labeling was performed in an automated 
fashion on an xt PAL (CTC analysis) as described in 
Kanashova et al. [62]. Labeled samples were mixed in a 
1:1 ratio and purified using C18 stage-tips. Samples were 
measured by LC-MS/MS on a Q Exactive Orbitrap mass 
spectrometer (Thermo Scientific) connected to a Proxeon 
nano-LC system (Thermo Scientific) in a data-dependent 
acquisition mode using the top 10 peaks for HCD 
fragmentation. 5 μl of sample was injected and a four-
hour gradient (solvent A: 5 % acetonitrile, 0.1 % formic 
acid; solvent B: 80 % acetonitrile, 0.1 % formic acid) 
was applied eluting peptides at 4 % to 76 % acetonitrile 
using an in-house prepared nano-LC column (0.074 mm 
x 250 mm, 3 µm Reprosil C18, Dr. Maisch GmbH) at a 
flow rate of 0.25 μl/min. MS acquisition was performed 
at a resolution of 70.000 in the scan range from 300 to 
1700 m/z. Dynamic exclusion was set to 30 s and the 
normalized collision energy was specified to 26. Data 
were analyzed with MaxQuant, version 1.3.0.5 [65], using 
a multiplicity of 2 for dimethylation analysis (modified 
epsilon amino groups of lysine plus modified N-terminal 
amino groups). Carbamidomethylation was set as a fixed 
modification while oxidized methionines and acetylated 
N-termini were set as variable modifications. An FDR 
of 0.01 was applied and Andromeda-based search was 
performed using a mouse Uniprot database (June 2012). 
Normalized ratios of the proteinGroups output were 
used to determine proteins with differential abundances. 
Significantly regulated proteins were defined to have a 
fold-change of at least 2.
aCGH
Genomic DNA was extracted with Qiagen´s 
DNeasy Blood & Tissue kit. Samples were digested 
overnight with proteinase K, DNA purified with phenol/
chloroform/isoamylacohol pH 7.5-8 and labeled with 
Cy3; BALB/c reference DNA was labeled with Cy5. 
Labeling, fragmentation and hybridization to Agilent 
SurePrint G3, 4x180K arrays has been performed by 
Atlas Biolabs, Berlin, according to the manufacturer’s 
instruction. GFP-3T3 and vGPCR-3T3 cells have 
been analyzed in triplicates, vGPCR-TC#1 cells in 
quintuplicates and vGPCR-TC#2 cells in duplicates. 
Data were evaluated using the software Genomics Suite 
(Partek) using the segmentation algorithm with the 
following parameters to identify all major copy number 
changes while avoiding oversegmentation: Minimum 
number of probes in a region ≥ 10, segmentation p-value 
≤ 0.0001, signal to noise ratio 0.7, region parameter 
above ≥ 2.3 for amplifications, region parameter below ≤ 
1.7 for deletions, region p-value ≤ 0.001. Raw aCGH data 
have been deposited in ArrayExpress (accession number 
E-MTAB-3394).
In vivo tumor growth experiments
In vivo tumor growth experiments in mice were 
performed by EPO GmbH, Berlin-Buch, Germany. 
All mice were housed and cared for in accordance with 
state guidelines under an approved animal protocol. For 
each group, 8 male BALB/c mice aged 9-12 weeks were 
injected with 1*106 tumor cells in 50 µl sterile PBS + 
50 µl growth-factor reduced matrigel (BD Bioscience). 
Tumor growth was monitored regularly with a vernier 
caliper. Tumor volume was calculated using the modified 
ellipsoid formula.
Western blotting
Cells have been lysed using M-PER reagent 
(Thermo Scientific); protein concentration was measured 
by a BCA protein assay (Thermo Scientific). Cellular 
lysates have been denatured in reducing SDS-loading 
buffer, separated by SDS-PAGE (Bio-Rad) and transferred 
to nitrocellulose membrane by wet blotting. vGPCR 
protein levels were assessed using an anti-myc antibody 
(Biolegend, #626802). Additionally used antibodies: leptin 
receptor (US Biological, #L1671-03R), phosho-Jak2 
(#3776), phospho-Stat3 (#9145), phospho-Akt1 (#4060), 
phospho-Erk1/2 (#4377), all Cell Signaling Technology, 
β-actin (Abcam, #ab6276) and secondary HRP-conjugated 
antibodies from Jackson Immunoresearch. Western blots 
have been developed using ECL reagent (GE Healthcare). 
microRNA detection and quantification by stem-
loop RT-qPCR
The small RNA fraction was isolated using 
Ambion´s mirVana kit according to the manufacturer´s 
instruction. RNA quality was determined using Agilent´s 
Bioanalyzer 2100. RNA was reverse transcribed using 
a stem-loop primer specific for the mature form (5p) of 
mmu-miR-34a, b, c or sno202 as normalization control. 
Stem-loop primer have been designed according to 
Kramer [23], synthesized by BioTeZ (Berlin) and folded 
in a thermocycler using the following protocol: 10´ 95 
°C, followed by a temperature reduction of 2.5 K every 
30 s until 80 °C, 1 h at 75 °C, 68 °C, 65 °C, 62 °C and 
60 °C overnight (>10 h). qPCR was performed on an 
IQ5 thermocycler (Bio-Rad) using a universal reverse 
primer binding to the stem-loop region and a microRNA/
sno202-specific forward primer; miRNA expression was 
normalized to the small RNA sno202 (ΔcT method) using 


















Total RNA was isolated using ZymoResearch´s 
Quick-RNATM MiniPrep kit and RNA quality controlled 
using Agilent´s Bioanalyzer 2100. Up to 5 µg RNA 
was reverse transcribed with 10 µM OligodT18 primer 
(Thermo Scientific) and 5 Units Revert Aid H Minus 
reverse transcriptase (Thermo Scientific). The cDNA 
was quantified with a Nanodrop spectrometer (Thermo 
Scientific) and analyzed by realtime quantitative PCR using 
a SYBR green/fluorescin master mix on a BioRad IQ5 
realtime thermocycler. Relative gene expression changes 
have been determined with the ΔcT method normalizing 
to β-actin. Errors have been calculated via the standard 
deviation SD of the cT values: error bar = 2^-((cTgene - 






Validation of chip data by realtime RT-qPCR
Ten randomly selected genes from Figure 6 have 
been analyzed by realtime qPCR. RNA was isolated 
using RNAisoPlus (Takara Bio, Japan). 1 µg RNA was 
transcribed using OligodT18 primer and PrimeScript 
reverse transcriptase (Takara Bio). qPCRs have been 
performed on Smart Cycler II (Cepheid, USA) using the 
2X SYBR Premix Ex Taq II master mix (Takara Bio). 























Cells were seeded in 96 well plates at a 
concentration of 15.000 cells/well. On the following day, 
cells were starved for 24 hrs in serum-free DMEM before 
adding 0, 50, 100 or 250 ng/ml leptin (PeproTech). 24 
hrs after treatment, thiazolyl blue tetrazolium bromide 
(Sigma Aldrich) was added to a final concentration of 
0.5 mg/ml. 4 hours later, medium was removed and cells 
lysed in 50 µl MTT solvent (4 mM HCl, 0.1 % Nonidet 
P-40 in isopropanol) and absorption at 570 nm measured 
with a microplate photoreader (BioTek Instruments, 
USA).
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